Qlife Holding AB
SSTO:QLIFE0.93
SEK
-0.07
(-7.10%)
ISIN
SE0022574331
Return %
Stock
S&P 500
1Y
-56.47
14.20
3Y
-97.77
81.12
5Y
-99.99
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Thomas Warthoe
- Full Time Employees
- 4
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Ullevigatan 19 Gothenburg AB Sweden 411 40
- IPO Date
- Mar 2, 2020
- Website
- qlifeholding.com
- Similar Companies
- Business
- Qlife Holding AB (publ) (QLIFE.ST) develops, manufactures and sells in-vitro diagnostic analyzers, reagents and biomarker testing platforms focused on at-home and point-of-care health monitoring. The company offers the Egoo.Health platform, comprising a compact reusable device, disposable test capsules and companion software that delivers clinical-grade results from small blood samples with over 99% correlation to laboratory instruments; specific biomarkers include CRP (C-reactive protein), procalcitonin, Nt-proBNP, lipids, HbA1c, vitamin D, D-dimer, phenylalanine (PHE) for PKU self-testing, potassium and additional tests in development for congestive heart failure. Egoo enables self-testing for patients, consumers and healthcare professionals in segments such as hospital-at-home, pharmacies and direct-to-consumer markets, with applications targeting chronic conditions including phenylketonuria, rheumatoid arthritis, cancer, diabetes and cardiovascular disease. Founded in 2019 and headquartered in Helsingborg, Sweden, Qlife Holding operates primarily in Europe with expansion ambitions into the US and global markets through strategic partnerships; the company previously owned Danish subsidiary Qlife ApS, which developed core Egoo technology prior to its bankruptcy in July 2024. In recent developments, Qlife repurchases key assets including the patented Egoo.Health technology, goodwill, inventory and equipment from the Qlife ApS bankruptcy estate in August 2024 for MDKK 3.00 plus potential earn-out, funded by directed share and warrant issues raising MSEK 11.95; executes full exercise of related warrants in September 2024 generating MSEK 4.7 in proceeds; completes successful clinical study for Egoo PHE self-test in children and young people in August 2025, advancing to IVDR submission for EU and UK self-test approval; launches two new biomarker tests (nt-proBNP, potassium) into clinical trials in September 2025; increases and extends a credit facility to SEK 10.1 million in August 2025; and progresses a reverse takeover merger with China's Hipro Biotechnology via extended letter of intent through December 2025, integrating product lines such as Egoo P200, Egoo Q/P300 and Hipro A1 for hospital, pharmacy and consumer diagnostics, with Hipro's HbA1c test gaining FDA approval.